Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges

Dwight H. Owen, Nikolaos A. Trikalinos

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

ONC201 is an oral selective antagonist of the dopamine D2 receptor and direct activator of caseinolytic protease P. In a phase II study, ONC021 was shown to be well tolerated with notable efficacy in patients with the rare neuroendocrine neoplasms pheochromocytomas-paragangliomas, although biomarkers for activity remain to be elucidated.

Original languageEnglish
Pages (from-to)1748-1750
Number of pages3
JournalClinical Cancer Research
Volume28
Issue number9
DOIs
StatePublished - May 1 2022

Fingerprint

Dive into the research topics of 'Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges'. Together they form a unique fingerprint.

Cite this